BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Cattrini, C.
Lozano Mejorada, R.
Conteduca, V.
Ruiz-Vico, M.
Lolkema, M. P.
Lorente, D.
Sandhu, S.
Romero Laorden, N.
Loriot, Y.
Azad, A. A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
